Introduction: The aim of this study was to validate the new eighth edition of the TNM classification and to elucidate whether radiological solid size corresponds to pathological invasive size incorporated in this T factor.
Introduction
The new eighth edition of the TNM classification of lung cancer was published and launched in 2017. 1 The method of measuring tumor diameter has been dramatically changed in this revision, and the groundglass component in radiological findings and lepidic growth component of cancer cells in pathological findings are no longer counted as tumor diameter. 2 The concept of "in situ cancer" has also been introduced in adenocarcinoma, which is already used in squamous cell carcinoma. 3 Although there are various issues that remain to be solved, the concept of this revision is reasonable when considering that TNM classification was originally used as the classification of invasive cancer.
Because a ground-glass opacity (GGO) component in radiological findings was not counted as tumor diameter, pure ground-glass nodules (GGNs) 3 cm or smaller were regarded as in situ cancer and categorized as Tis. The size of solid components in lung nodules on a thin-section computed tomography (TSCT) scan, except for the GGO component, is involved in the decision regarding clinical T factors.
Correspondingly, a lepidic growth pattern in pathological findings of lung adenocarcinoma is considered a noninvasive lesion, and a pure lepidic growth pattern of cancer cells 3 cm or smaller is classified as adenocarcinoma in situ (AIS). The invasive components to be measured include any histologic subtype other than a lepidic pattern (such as acinar, papillary, micropapillary, solid, colloid, fetal, or invasive mucinous adenocarcinoma) and tumor cells infiltrating myofibroblastic stroma. The size of the invasive component in lung tumors in pathological findings, except for the lepidic growth component of cancer cells, is involved in the decision regarding pathological T factors.
In view of this background, the correlation between clinical evaluation and postoperative (i.e., pathological) evaluation of the lung cancer is especially important, and the correlation between solid size on preoperative TSCT scan and invasive size in the pathological findings is also the centerpiece of this classification.
The aim of this study was to validate the new eighth edition of TNM classification in both the clinical and pathological settings from the perspective of a survival curve of each stage and to examine the correlation between radiological solid size and size of the pathological invasive components that were newly defined.
Patients and Methods

Patient Selection
The objective for this retrospective study was to evaluate the prognosis of 2013 patients with lung cancer who underwent surgery between January 2003 and December 2011 at the National Cancer Center Hospital East, Kashiwa, Japan. Of these patients, 1866 who underwent complete resection by lobectomy with lymph node dissection, did not receive preoperative therapy, and had no distant metastasis and no low-grade malignancy of carcinoid, mucoepidermoid carcinoma, or adenoid cystic carcinoma according to pathological examination were included in this study population. We excluded 74 patients who showed undetectable tumors on preoperative computed tomography (CT) scan (n ¼ 1), did not have an available preoperative TSCT scan (n ¼ 9), had synchronous lung cancer (n ¼ 62), or had a data deficiency (n ¼ 2). We finally analyzed the clinical (age, sex, smoking history, preoperative serum carcinoembryonic antigen level, maximum tumor size, solid size, GGO component, and clinical stage based on the seventh edition and the eighth edition), pathological (pathological type and pathological maximum tumor size, invasive size, lepidic component, and pathological stage based on the seventh edition and the eighth edition), and prognostic data of the 1792 patients shown in Figure 1 . The protocol containing full details regarding the data collection methods from our anonymous database of primary lung cancer newly revised for this study, the statistical methods, and the waiver of obtaining informed consent from each patient was approved by the institutional review board in September 2016 (approval number 2016-189).
Radiological Evaluation of TSCT Scans and Clinical Staging Policy
Contrast-enhanced CT scans at 5-to 10-mm collimation of the chest and upper abdomen were obtained to assess the clinical staging of all patients with lung cancer. In addition, TSCT images at 1-to 2-mm collimation were reconstructed for evaluating primary tumor size, GGO component, solid size, and other factors. The X-vigor CT system (Toshiba Medical Systems, Tokyo, Japan) was used to obtain the CT scans, and the CT images were evaluated on a monitor display with a window level of À600 HU and a window width of 1800 HU. Two observers (K.A. and S.K.), who were unaware of the pathological findings and prognosis, reviewed each lung nodule on the preoperative TSCT scans. A solid opacity on a TSCT image was defined as an area of increased opacification that completely obscured the underlying vascular structures. A GGO was defined as increased hazy density in an area without obscuring the underlying vascular structure. 4, 5 We measured the maximum diameter of the tumor including a GGO and a solid part only in the lung window. Discrepancies in measurement interpretation between the observers were resolved by consensus. Disease stage during the study period was determined according to the sixth or the seventh edition of the TNM classification, but for this report, we also reclassified the study population according to the eighth edition of the TNM classification. 1, 6, 7 Clinical lymph node staging was performed by preoperative contrast CT and/ or positron emission tomography. We defined cN2 as a mediastinal lymph node larger than 1.0 cm in the shortest dimension on CT image and/or showing abnormal accumulation of fludeoxyglucose F 18. If required, we performed endobronchial ultrasoundguided transbronchial needle aspiration cytology for N staging and for determining indication for surgery. A survival curve was constructed according to each of these classified groups, and median survival times and 5-year survival rates were calculated.
Pathological Evaluation
Surgical specimens were fixed with 10% formalin and embedded in paraffin. Serial 4-mm sections were stained with hematoxylin and eosin and by the Alcian blue-periodic acid-Schiff method for cytoplasmic mucin production. We used elastica van Gieson or Victoria blue-van Gieson staining to visualize elastic fibers and evaluate vascular and pleural invasion for all cases. Lymphatic permeation was basically evaluated with hematoxylin and eosin-stained slides, but we often used D2-40 stain to highlight lymphatic vessels. Histological typing was determined according to the third edition of the WHO classification of cell types, but for this study, one pathologist (G. I.) and one clinician (S. K.) also reevaluated all cases using the new fourth edition of the WHO classification of tumors of the lung, pleura, thymus, and heart (2015). 8 In particular, lung adenocarcinoma was newly defined by the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification, and the concepts of AIS and minimally invasive adenocarcinoma were also introduced into the T descriptor of the new eighth edition of the TNM classification.
1,2 One of the most important points for pathological diagnosis of adenocarcinoma is how to measure invasive size microscopically. The invasive component was clearly defined in the International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society consensus report as follows: (1) histological subtypes other than a lepidic pattern (i.e., acinar, papillary, micropapillary, and/or solid) or (2) tumor cells infiltrating myofibroblastic stroma. We reevaluated all lung adenocarcinomas and measured the invasive size of all adenocarcinomas. For comparison between radiological solid size and invasive size, we also determined invasive size in the other pathological types of lung cancer by using the maximum tumor diameter. 3 The discrepancies in interpretation between observers were resolved by consensus, and each size was measured one time only for this study alone; therefore, the interobserver and intraobserver variation remain issues to be solved in the future.
Correlation between Radiological Solid Size on TSCT Image and Pathological Invasive Size
Pearson's correlation coefficient was calculated to elucidate the correlation between radiological solid size on TSCT and pathological invasive size by using the third edition of the WHO classification of cell types. The regression line was also calculated.
Patient Follow-up
Patients were evaluated at 3-month intervals for the first 2 years and typically at 6-month intervals thereafter on an outpatient basis. The follow-up evaluation included physical examination, chest radiography, and blood testing, including for pertinent tumor markers. Whenever any symptoms or signs of recurrence were detected, further evaluations were conducted, including CT of the chest and abdomen, brain magnetic resonance imaging, and bone scintigraphy. After 2004, integrated positron emission tomography/CT was also performed when necessary. All patients had follow-up for at least 5 years after surgery and up to 10 years, because some patients who underwent complete resection for lung cancer sometimes experienced recurrence after 5 years. 9, 10 Recurrence or survival information was obtained as far as possible by a follow-up letter in the case of patients who could not make regular clinic visits for up to 10 years. Recurrence was diagnosed on the basis of compatible physical examination and diagnostic imaging findings, and the diagnosis was histologically confirmed when clinically feasible. The length of overall survival was defined as the interval in months between the date of surgical intervention and the last follow-up date or death due to any cause. Observations were censored at the last follow-up when the patient was alive or lost to follow-up. The date of data cutoff was May 2016 at our institution.
Statistical Analysis
All cumulative overall survival rates and median survival rates were estimated by the Kaplan-Meier method. To evaluate the prognostic impact of the seventh and eighth editions of the TNM classification, hazard ratios and their 95% confidence intervals were estimated by using a Cox proportional hazards model. As a discriminative measure, model-based concordance probability estimates (CPEs) 11 and Akaike's information criteria (AIC) for a univariable Cox model including the indicator of the clinical or pathological TNM classification (the seventh and eighth editions) only were calculated.
Agreement between clinical and pathological classification was assessed by using weighted k coefficients based on Fleiss-Cohen weights. Pearson's correlation coefficient was used to elucidate the correlation between solid size in tumors using by preoperative TSCT images and the size of pathological invasive components according to the new 2015 WHO classification. 
Results
The total number of patients in this cohort was 1792, and the median follow-up period was 86.4 months (range 1-150 months). Patient clinical characteristics are summarized in Table 1 . Most of the patients were men (1155 patients [64%]), and 546 (30%) had never smoked. The average maximum tumor diameter (±SD), including the GGO component, was 33 plus or minus 17 mm. The average size of the tumor solid component was 30 plus or minus 18 mm. The GGO component was recognized in 473 of 1792 patients (26%). Clinical stages according to the seventh edition of TNM and the eighth edition of TNM are shown in Table 1 . Clinical Tis (cTis) is defined as a lung tumor without a radiological solid component (i.e., a pure GGN) and with a size of 3 cm or less. The number of cTis patients was 21 (1%). There was no clinical stage IV patient in this cohort.
Otherwise, patient pathological characteristics are summarized in Table 2 . Adenocarcinomas were predominantly found in 1214 of 1972 patients (68%). The average maximum tumor diameter, including the lepidic component (pathologically defined), plus or minus the SD was 33 plus or minus 18 mm. The pathological invasive size was 27 plus or minus 19 mm. The lepidic component was recognized in 879 of 1214 patients with adenocarcinoma (72%). The pathological stages according to the seventh edition and eighth editions of the TNM are also shown in Table 2 . Pathological Tis (pTis) including AIS, which was newly defined in this revision, was found in 29 patients (2%).
The correspondence Figure 2A and B shows overall survival curves by clinical stage according to the seventh edition and new eighth edition of the TNM classification for this entire cohort available for reclassification, respectively. In this revision, clinical stage IA has been divided into three categories (IA1, IA2, and IA3). The 5-year survival rates of categories IA1, IA2, and IA3 were 95%, 84%, and 76%, respectively, and they were sufficiently distinct from one another. The 5-year survival rate of clinical stage 0 (TisN0M0) was 100%. The survival curves of other stages were quite distinct at each stage. Figure 2C and D shows the overall survival curves by pathological stage according to the seventh and new eighth edition of the TNM classification, respectively. Pathological stage IA has also been divided into three categories (IA1, IA2, and IA3). The 5-year survival rates of IA1, IA2, and IA3 were 95%, 91%, and 81%, respectively, and they were sufficiently distinct from each other. The 5-year survival rate of pathological stage 0 (TisN0M0) was 100%. The survival curves of other stages were quite distinct at each stage. Table 3 is a summary of hazard ratio, CPE, and AIC by each stage. The low level of AIC denotes the goodness of model fit. The eighth edition of the TNM classification provided a better fit of the model than the seventh edition by comparison of AIC values. The CPE of the eighth edition is higher than that of the seventh edition. This result showed that the eighth edition is superior to the seventh edition in discriminatory power for overall survival. Figure 3 shows a scatter plot of the two variables radiological solid size measured on preoperative TSCT image and size of the invasive component evaluated microscopically. These two variables showed a positive linear relationship, and Pearson's correlation coefficient (r) was calculated as 0.83. This indicated that the strength of association between the radiological solid size and the pathological invasive size was relatively high and that the correlation coefficient was highly significant (p < 0.01). The regression formula of this scatter plot was as follows:
This coefficient of 0.874 implied that the radiological solid size was slightly overestimated compared with the pathological invasive size.
Discussion
The development of CT technology has enabled increased detection of pure GGNs and part solid GGNs. 12 Many researchers have reported that patients with these tumors have a better prognosis than those without the GGO component. 4, [13] [14] [15] Some researchers have insisted that a solid size on TSCT image indicates patient prognosis better than a classic tumor size. 16 Other researchers have believed that the consolidation-to-tumor ratio indicates patient prognosis better than a classic tumor size does. 4, 12, 14, 15 In both assertions, the existence of a GGO component in a lung nodule implied a good prognosis for the patient with lung cancer. This concept, which had been reported by many past studies, has been adequately addressed in this new TNM classification and incorporated into the clinical and pathological T descriptors. 2 The present study has shown the feasibility of the new eighth edition of the TNM classification from the perspective of overall survival by using a mature data set (the median follow-up period of this data was 86.4 months) and the correlation between radiological evaluation on TSCT scan and pathological evaluation. Evaluation of a GGO component requires TSCT images, and we reassessed TSCT images for all cases in this study. The 5-year survival rate in patients with pure GGN and pure lepidic growth cancer without an invasive component was 100%. This group was compatible to that with in situ cancer. The subgroups of patients with tumor size of 3 cm or smaller (IA1, IA2, and IA3) showed well-distinct survival curves, as reported in a previous study. Lung nodules with the GGO component on TSCT image are being detected in our country with increasing frequency. In our study cohort, 473 of 1792 lung nodules (26%) included a GGO component. Correspondingly, lung cancer with a lepidic component has also been detected in pathological evaluation with increasingly frequency (72%). The new staging according to the solid size showed a different prognosis for each stage clinically and pathologically. Additionally, the solid size on TSCT image and the pathological invasive size showed a linear correlation. The Pearson correlation coefficient of 0.83 indicated a strong association between these two parameters. The regression formula was y ¼ 0.874x þ 1.344. The slope of 0.874 (<1) implies that the radiological solid size was slightly overestimated compared with the pathological invasive size. One of the reasons for this is that lung collapse by lepidic growth of cancer cells in pathological findings is recognized as a solid component of the lung nodule on CT. However, the result of linear correlation showed that the discrepancy between clinical and pathological evaluation may be relatively improved, and that this TNM stage may reflect a patient's prognosis more exactly. Some clinical trials investigating limited resection of the lung for small NSCLC with the method of measuring tumor size on the basis of the seventh edition of the TNM classification are still ongoing. These upcoming results may be promising, but new therapeutic approaches according to these new staging groups should also be developed in the future.
This classification included some inherent essential issues; for example, TSCT images of the tumor are mandatory for the measurement of solid size, and a pathologist specialized in the pathological diagnosis of lung cancer is necessary. We sometimes encounter cases in which it is difficult to identify the border of the solid component or determine whether there are solid or ground-glass components in lung nodules. Therefore, intraobservational and interobservational reproducibility will be a larger issue when determining solid size than classic tumor size. This also applies to the measurement of pathological invasive size. Some reports have indicated the difficulty of concordance in subclassification of adenocarcinoma. 18, 19 These issues should be investigated in the future.
The limitations of this study were as follows: it was a retrospective study using data acquired at our single institution, and the data were mainly obtained from surgical cases. Therefore, the survival curves for higher than stage III disease will be limited in the reliability to some extent. Radiological evaluation was performed by only two clinicians, and pathological evaluation was performed by only one pathologist and one clinician. The discrepancies in interpretation between observers were resolved by consensus. The measurements in each CT image and pathological slide were made one time only. So, we have no data about intraobservational and interobservational reproducibility. When we measure tumor size on CT image at on a different occasion or when others measure it again, these results may be different from the first measurement. This is a limitation of this study.
In conclusion, as there are still many issues to be resolved, this revised version of TNM classification was feasible in this cohort at our single institution and reflected patient prognosis more accurately than the previous classification. 
